1-6 of 6
Harry P. Erba
Close
Sort by
Journal Articles

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph + acute lymphoblastic leukemia

Clinical Trials & Observations
Anjali S. Advani, Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1279–1285.
https://doi.org/10.1182/bloodadvances.2022008216
Published: 2023
Includes: Supplemental data
Journal Articles

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

Clinical Trials & Observations
Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Frederick R. Appelbaum, Harry P. Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson, Anjali S. Advani, Wendy Stock, Selina M. Luger
Journal: Blood Advances
Blood Adv (2023) 7 (2): 196–204.
https://doi.org/10.1182/bloodadvances.2022007791
Published: 2023
Includes: Supplemental data
Journal Articles

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Clinical Trials & Observations
Lori Muffly, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S. Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow, Matthew C. Foster, Harry P. Erba, Frederick R. Appelbaum, Richard A. Larson, Theresa H.M. Keegan, Wendy Stock
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4085–4092.
https://doi.org/10.1182/bloodadvances.2022007197
Published: 2022
Includes: Supplemental data
Journal Articles

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Clinical Trials & Observations
Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1683–1689.
https://doi.org/10.1182/bloodadvances.2019001278
Published: 2020
Journal Articles

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Clinical Trials & Observations
Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1939–1949.
https://doi.org/10.1182/bloodadvances.2019030916
Published: 2019
Journal Articles

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

Clinical Trials & Observations
Farhad Ravandi, Megan Othus, Susan M. O'Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y. C. Wong, Martin S. Tallman, Elisabeth Paietta, Janis Racevskis, Geoffrey L. Uy, Mary Horowitz, Naoko Takebe, Richard Little, Uma Borate, Partow Kebriaei, Laura Kingsbury, Hagop M. Kantarjian, Jerald P. Radich, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2016) 1 (3): 250–259.
https://doi.org/10.1182/bloodadvances.2016001495
Published: 2016
Includes: Supplemental data